GCT has just been awarded a new clinical study related to SARS-CoV-2.

It is a double-blind, randomized, placebo-controlled, phase II study in hospitalized patients infected with severe acute respiratory syndrome-coronavirus-2. The Sponsor is a Swiss Biotech.

For this study, 150 patients will be enrolled at the Russian sites.

Coronavirus infection COVID-19 affects different groups of people to different degrees. Some of the patients with moderate to severe cases require hospitalization.

“For over a year now we have been in a difficult situation due to the pandemic. We are grateful to be a part of many СOVID-19 trials aiming to improve it,” said Dr. Eugene Selivra, GCT CEO. GCT has built up a solid portfolio of COVID-19 trials. Contact us at bd@gctrials.com to find out more and discuss your project.